Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Rapid Responses to:
|
|
Rapid Responses published:
|
|
|||
|
Anusch Yazdani, Gynaecologist Mater Hospital, Brisbane
Send response to journal:
|
I wonder what the implications of this action are for the use of Implanon... Etonogestel, the active component in Implanon, is the biologically active metabolite of desogestrel, the progestogen of one of the oral contraceptives implicated in this class action. The recent meta- analysis by Kemmeren et al (BMJ 2001 Jul 21;323(7305):131-4) suggests an overall adjusted odds ratio for third versus second generation oral contraceptives of 1.7 for deep venous thrombosis. Kemmeren et al (Thromb Haemost 2002 Feb;87(2):199-205)attribute this increased risk to a less effective compensation of the thrombotic effect of ethinylestradiol by desogestrel and desogestrel per se may therefore be vindicated. Unfortunately, legal action is not always based on sound scientific evidence and this simple association may demand further caution. |
|||
|
|
|||
|
Friedrich Flachsbart, general medicine 37085 Göttingen
Send response to journal:
|
Dear Sir, In cases of thrombosis in the patient's family You should search for a genetic mutation like Factor V (Leiden). Any symptoms of minor pulmonary embolism should at once induce D- Dimer(ELISA)-testing to exclude deep-vein-thrombosis. This is the only way to minimize the risk! Sincerely Yours
|
|||